Basel, 20 September, 2023 – The Swiss biotech company TOLREMO therapeutics AG recently completed a successful Series A financing, bringing the total amount raised to USD 39 million (CHF 34.1 million). BioMedPartners AG led the round, and Pierre Fabre Invest joined as an investor. It’s TOLREMO’s mission to combat non-genetic drug resistance in cancer treatment.
Enhancing cancer treatment
TOLREMO’s flagship candidate, TT125-802, an oral CBP/p300 bromodomain inhibitor, aims to disrupt early cancer resistance pathways. Funds will initiate a Phase 1 monotherapy study to evaluate safety, pharmacokinetics, pharmacodynamics and efficacy. Next, TT125-802 will be assessed in combination with targeted therapies like KRAS, EGFR or AR inhibitors.
TOLREMO targets early resistance pathways, potentially enhancing treatment durability. Stefanie Flückiger-Mangual, PhD, CEO of TOLREMO, welcomed Pierre Fabre Invest’s support for fast-tracking TT125-802 development.
Empowering leadership
In the context of the financing, two experts joined TOLREMO: Julie M. Cherrington, PhD, has been appointed Chair of the Board of Directors. “I look forward to supporting the team at this critical juncture as the company advances its lead program into clinical development,” she said. Francesco Hofmann, PhD, of Pierre Fabre Laboratories, joined TOLREMO’s Scientific Advisory Board. He commented on Pierre Fabre Invest’s involvement: “This new investment is very consistent with our renewed strategy to focus our R&D portfolio on targeted therapies.”
